Advertisement
ADCT vs CLRB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADCT is a Hold and CLRB is a Hold.
Aroon Indicator for ADCT shows an upward move is likely
ADCT's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 151 similar instances where the Aroon Indicator showed a similar pattern. In 126 of the 151 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on ADCT as a result. In 72 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
ADCT moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADCT crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +8.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADCT advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ADCT moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 53 cases where ADCT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ADCT turned negative on October 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ADCT broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.839) is normal, around the industry mean (10.407). P/E Ratio (-2.586) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (1.967) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ADCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for CLRB turns negative, indicating new downward trend
CLRB saw its Momentum Indicator move below the 0 level on September 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CLRB turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLRB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CLRB's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in 184 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CLRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.370) is normal, around the industry mean (2.973). P/E Ratio (-0.529) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CLRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ADCT | CLRB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 46 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 50 | 93 | |
P/E GROWTH RATING 1..100 | 64 | 8 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADCT's Valuation (18) in the null industry is in the same range as CLRB (46) in the Biotechnology industry. This means that ADCT’s stock grew similarly to CLRB’s over the last 12 months.
ADCT's Profit vs Risk Rating (100) in the null industry is in the same range as CLRB (100) in the Biotechnology industry. This means that ADCT’s stock grew similarly to CLRB’s over the last 12 months.
CLRB's SMR Rating (99) in the Biotechnology industry is in the same range as ADCT (100) in the null industry. This means that CLRB’s stock grew similarly to ADCT’s over the last 12 months.
ADCT's Price Growth Rating (50) in the null industry is somewhat better than the same rating for CLRB (93) in the Biotechnology industry. This means that ADCT’s stock grew somewhat faster than CLRB’s over the last 12 months.
CLRB's P/E Growth Rating (8) in the Biotechnology industry is somewhat better than the same rating for ADCT (64) in the null industry. This means that CLRB’s stock grew somewhat faster than ADCT’s over the last 12 months.
| ADCT | CLRB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 80% | 2 days ago 90% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 87% |
| Advances ODDS (%) | 3 days ago 81% | 2 days ago 81% |
| Declines ODDS (%) | 9 days ago 90% | 4 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADCT’s FA Score shows that 1 FA rating(s) are green while CLRB’s FA Score has 1 green FA rating(s).
- ADCT’s FA Score: 1 green, 4 red.
- CLRB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADCT’s TA Score shows that 5 TA indicator(s) are bullish while CLRB’s TA Score has 4 bullish TA indicator(s).
- ADCT’s TA Score: 5 bullish, 5 bearish.
- CLRB’s TA Score: 4 bullish, 4 bearish.
Price Growth
ADCT (@Pharmaceuticals: Generic) experienced а +7.38% price change this week, while CLRB (@Biotechnology) price change was -1.68% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
ADCT is expected to report earnings on Nov 09, 2026.
CLRB is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.00% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement